These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
229 related items for PubMed ID: 8879451
1. Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis. Schaefer BM, Jaeger C, Drepper E, Kramer MD. Autoimmunity; 1996; 23(3):155-64. PubMed ID: 8879451 [Abstract] [Full Text] [Related]
13. Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis. Gissler HM, Frank R, Kramer MD. Br J Dermatol; 1993 Jun; 128(6):612-8. PubMed ID: 7687853 [Abstract] [Full Text] [Related]
14. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration. McNeill H, Jensen PJ. Cell Regul; 1990 Oct; 1(11):843-52. PubMed ID: 1965151 [Abstract] [Full Text] [Related]
15. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface. Ragno P, Montuori N, Rossi G. Eur J Biochem; 1995 Oct 15; 233(2):514-9. PubMed ID: 7588796 [Abstract] [Full Text] [Related]
16. Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester. Lund LR, Eriksen J, Ralfkiaer E, Rømer J. J Invest Dermatol; 1996 Apr 15; 106(4):622-30. PubMed ID: 8617995 [Abstract] [Full Text] [Related]
17. Plasminogen activator inhibitor type-2 in the lesional epidermis of lupus erythematosus. Bechtel MJ, Schaefer BM, Kramer MD. Br J Dermatol; 1996 Mar 15; 134(3):411-9. PubMed ID: 8731662 [Abstract] [Full Text] [Related]
18. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Buø L, Meling GI, Karlsrud TS, Johansen HT, Aasen AO. Hum Pathol; 1995 Oct 15; 26(10):1133-8. PubMed ID: 7557947 [Abstract] [Full Text] [Related]
19. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. Cubellis MV, Wun TC, Blasi F. EMBO J; 1990 Apr 15; 9(4):1079-85. PubMed ID: 2157592 [Abstract] [Full Text] [Related]
20. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. Ellis V, Wun TC, Behrendt N, Rønne E, Danø K. J Biol Chem; 1990 Jun 15; 265(17):9904-8. PubMed ID: 2161846 [Abstract] [Full Text] [Related] Page: [Next] [New Search]